SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-23-033755
Filing Date
2023-07-21
Accepted
2023-07-21 09:00:44
Documents
12
Period of Report
2023-07-19
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 8-K evok-20230719.htm   iXBRL 8-K 60526
  Complete submission text file 0000950170-23-033755.txt   175359

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT evok-20230719.xsd EX-101.SCH 2478
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT evok-20230719_lab.xml EX-101.LAB 12806
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT evok-20230719_pre.xml EX-101.PRE 9459
6 EXTRACTED XBRL INSTANCE DOCUMENT evok-20230719_htm.xml XML 4534
Mailing Address 420 STEVENS AVENUE SUITE 370 SOLANA BEACH CA 92075
Business Address 420 STEVENS AVENUE SUITE 370 SOLANA BEACH CA 92075 858-345-1494
Evoke Pharma Inc (Filer) CIK: 0001403708 (see all company filings)

IRS No.: 208447886 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36075 | Film No.: 231101193
SIC: 2834 Pharmaceutical Preparations